Zhongxin Jingwei, December 16 - On the morning of december 16, WuXi Biologics issued an announcement on the Hong Kong Stock Exchange that the company had learned that the company's shares had unusual fluctuations in stock price and trading volume on December 15, 2021.
WuXi Biologics said that as of the date of this announcement, the Company was not aware of any changes in the regulatory regime that could materially adversely affect its business operations. The company will continue to work hard to empower its partners and be confident in continued high-speed growth ahead. In addition, the Board of Directors has decided to use the repurchase authorization to repurchase shares on the open market from time to time for a total price not exceeding US$500 million.
Screenshot source: Wind
Yesterday (15th), WuXi Biologics closed down 19.24%, and once fell more than 24% intraday. In addition, Hong Kong-listed biomedical stocks collectively dived, of which Clover Bio fell more than 18% and Rongchang Bio fell 14%. The anti-epidemic sector also fell collectively, with Pioneering Pharmaceuticals-B (09939) falling more than 8%, and Junshi Bio (01877) falling more than 7%. WuXi AppTec also suffered a "double kill" of AH shares, of which A shares fell to a halt and H shares fell by 19.06%. For the sharp decline in stock prices, relevant people from WuXi App & Pr. App Said that the current operation of the company is normal. (Zhongxin Jingwei APP)
![WuXi Biologics: We are not aware of any regulatory regime changes that may have a material adverse impact on our operations[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)